# N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Source: https://onco.cc/trials/nct06061809/  
OnCo record `nct06061809` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bevacizumab and Nogapendekin alfa inbakicept in glioma & glioblastoma, run by ImmunityBio, Inc., active and no longer recruiting.

## Summary

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is a phase 2 interventional study registered as NCT06061809 by ImmunityBio, Inc., with 34 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Bevacizumab, PD-L1 t-haNK, N-803 and Tumor Treating Fields (TTFields, 200 kHz).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06061809
- Phase: 2
- Setting: Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and Randomized Phase 2B Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields With or Without PD-L1 t-haNK in Participants With Recurrent or Progressive Glioblastoma
- Sponsor: ImmunityBio, Inc.
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT06061809: https://clinicaltrials.gov/study/NCT06061809

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06061809.json